MaxCyte Statistics
Total Valuation
MaxCyte has a market cap or net worth of $349.27 million. The enterprise value is $221.49 million.
Important Dates
The last earnings date was Wednesday, November 6, 2024, after market close.
| Earnings Date | Nov 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
MaxCyte has 105.48 million shares outstanding. The number of shares has increased by 1.47% in one year.
| Current Share Class | 105.48M |
| Shares Outstanding | 105.48M |
| Shares Change (YoY) | +1.47% |
| Shares Change (QoQ) | +0.45% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 95.94M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 8.63 |
| PB Ratio | n/a |
| P/TBV Ratio | 1.64 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.86 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.81, with a Debt / Equity ratio of 0.09.
| Current Ratio | 9.81 |
| Quick Ratio | 8.99 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -16.00% and return on invested capital (ROIC) is -12.05%.
| Return on Equity (ROE) | -16.00% |
| Return on Assets (ROA) | -11.25% |
| Return on Capital (ROIC) | -12.05% |
| Revenue Per Employee | $318,874 |
| Profits Per Employee | -$249,902 |
| Employee Count | 143 |
| Asset Turnover | 0.18 |
| Inventory Turnover | 0.56 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -15.90% in the last 52 weeks. The beta is 1.16, so MaxCyte's price volatility has been higher than the market average.
| Beta (5Y) | 1.16 |
| 52-Week Price Change | -15.90% |
| 50-Day Moving Average | 3.75 |
| 200-Day Moving Average | 4.18 |
| Relative Strength Index (RSI) | 45.84 |
| Average Volume (20 Days) | 599,508 |
Short Selling Information
The latest short interest is 3.24 million, so 3.07% of the outstanding shares have been sold short.
| Short Interest | 3.24M |
| Short Previous Month | 3.51M |
| Short % of Shares Out | 3.07% |
| Short % of Float | 3.38% |
| Short Ratio (days to cover) | 11.38 |
Income Statement
In the last 12 months, MaxCyte had revenue of $45.60 million and -$35.74 million in losses. Loss per share was -$0.34.
| Revenue | 45.60M |
| Gross Profit | 39.21M |
| Operating Income | -46.39M |
| Pretax Income | -35.43M |
| Net Income | -35.74M |
| EBITDA | -42.03M |
| EBIT | -46.39M |
| Loss Per Share | -$0.34 |
Full Income StatementBalance Sheet
The company has $153.83 million in cash and $18.32 million in debt, giving a net cash position of $135.51 million or $1.28 per share.
| Cash & Cash Equivalents | 153.83M |
| Total Debt | 18.32M |
| Net Cash | 135.51M |
| Net Cash Per Share | $1.28 |
| Equity (Book Value) | 213.30M |
| Book Value Per Share | 2.03 |
| Working Capital | 155.29M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$18.81 million and capital expenditures -$2.42 million, giving a free cash flow of -$21.23 million.
| Operating Cash Flow | -18.81M |
| Capital Expenditures | -2.42M |
| Free Cash Flow | -21.23M |
| FCF Per Share | -$0.20 |
Full Cash Flow StatementMargins
Gross margin is 85.98%, with operating and profit margins of -101.74% and -78.37%.
| Gross Margin | 85.98% |
| Operating Margin | -101.74% |
| Pretax Margin | -78.37% |
| Profit Margin | -78.37% |
| EBITDA Margin | -92.18% |
| EBIT Margin | -101.74% |
| FCF Margin | -55.87% |
Dividends & Yields
MaxCyte does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.47% |
| Shareholder Yield | -1.47% |
| Earnings Yield | -10.23% |
| FCF Yield | -6.08% |
Analyst Forecast
The average price target for MaxCyte is $8.67, which is 148.42% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $8.67 |
| Price Target Difference | 148.42% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 28.39% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MaxCyte has an Altman Z-Score of 6.72 and a Piotroski F-Score of 2.
| Altman Z-Score | 6.72 |
| Piotroski F-Score | 2 |